Chemistry:HOPO 14-1

From HandWiki
Revision as of 01:12, 27 June 2023 by NBrushPhys (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Investigational drug product for treatment of heavy metal poisoning
3,4,3-LI(1,2-HOPO)
3,4,3-LI(1,2-HOPO).svg
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC34H38N8O12
Molar mass750.722 g·mol−1
3D model (JSmol)

HOPO 14-1 is an investigational drug product for removing radioactive contaminants from the body. It is an oral capsule designed to act as a defence against radioactive threats such as nuclear power plant accidents or dirty bomb attacks.[1][2] The active ingredient is the hydroxypyridinone ligand 3,4,3-LI(1,2-HOPO), which is a powerful chelating agent.[1][3] HOPO 14-1 works by selectively binding to heavy metals in the body and forming a complex that the body can naturally excrete.[4] The drug is also being studied as a treatment for other forms of heavy metal toxicity, including lead poisoning and exposure to gadolinium from MRI contrast agents.[5][6][7][8] HOPO 14-1 was developed at Lawrence Berkeley National Laboratory by actinide chemist Rebecca Abergel. Abergel and former postdoc Julian Avery Rees co-founded HOPO Therapeutics, a company commercializing HOPO 14-1 and other treatments for heavy metal poisoning.

References

  1. ↑ 1.0 1.1 "First-in-human trial of oral drug to remove radioactive contamination begins" (in EN). 2023-05-15. https://www.nih.gov/news-events/news-releases/first-human-trial-oral-drug-remove-radioactive-contamination-begins. 
  2. ↑ "Dirty-bomb antidote: Drug trial begins in US" (in en-GB). BBC News. 2023-05-16. https://www.bbc.com/news/health-65595250. 
  3. ↑ "Chelation Behaviors of 3,4,3-LI(1,2-HOPO) with Lanthanides and Actinides Implicated by Molecular Dynamics Simulations". Inorganic Chemistry 62 (10): 4304–4313. March 2023. doi:10.1021/acs.inorgchem.2c04460. PMID 36847745. 
  4. ↑ "Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO)". Health Physics 99 (3): 401–407. September 2010. doi:10.1097/HP.0b013e3181c21273. PMID 20699704. 
  5. ↑ "Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents". Scientific Reports 8 (1): 4419. March 2018. doi:10.1038/s41598-018-22511-6. PMID 29535330. Bibcode: 2018NatSR...8.4419R. 
  6. ↑ "This Anti-Nuclear-Contimation Pill Could Also Help MRI Patients" (in EN). 2019-09-12. https://newscenter.lbl.gov/2019/09/12/how-an-anti-nuclear-contamination-pill-could-also-help-mri-patients/. 
  7. ↑ "Rebecca Abergel - Bakar Fellows Program" (in EN). 2021-10-21. https://bakarfellows.berkeley.edu/profile/rebecca-abergel/. 
  8. ↑ "HOPO Therapeutics" (in EN). 2023-05-29. https://www.hopotx.com. 

See also

  • Diethylenetriamine pentaacetate



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:HOPO_14-1&oldid=2984578"